A Study of LY3113593 in Participants With Chronic Kidney Disease

I7C-MC-FEAC -

The purpose of this study is to determine the safety of the study drug, LY3113593. The study will also evaluate how much of the study drug gets into the blood stream, how long it takes the body to remove the study drug, and what effect the study drug has on the body. This study is not intended to treat anemia of chronic kidney disease. Participants will receive up to four injections of LY3113593 or placebo into a vein.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Chronic Kidney Disease
What the trial is testing?
LY3113593
Could I receive a Placebo?
Yes
Enrollment Goal
7
Trial Dates
Nov 17, 2015 - Jun 22, 2016
How long will I be in the trial?
Your participation could last up to 26 weeks and include 14 visits to the study center.
Trial Phase
I

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.